Literature DB >> 28879531

PD1 blockade with low-dose nivolumab in NK/T cell lymphoma failing L-asparaginase: efficacy and safety.

Thomas S Y Chan1, Jamilla Li1, Florence Loong2, Pek-Lan Khong3, Eric Tse1, Yok-Lam Kwong4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28879531     DOI： 10.1007/s00277-017-3127-2

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  25 in total

1.  Genetic alterations of 9p24 in lymphomas and their impact for cancer (immuno-)therapy.

Authors:  Thomas Menter; Alexandar Tzankov
Journal:  Virchows Arch       Date:  2018-08-21       Impact factor: 4.064

Review 2.  NK/T Cell Lymphoma: Updates in Therapy.

Authors:  Ritsuro Suzuki
Journal:  Curr Hematol Malig Rep       Date:  2018-02       Impact factor: 3.952

Review 3.  Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome.

Authors:  Andres Chang; Danielle Schlafer; Christopher R Flowers; Pamela B Allen
Journal:  Expert Opin Investig Drugs       Date:  2017-12-24       Impact factor: 6.206

Review 4.  Novel Immunotherapies for T Cell Lymphoma and Leukemia.

Authors:  Paola Ghione; Alison J Moskowitz; Nadia E K De Paola; Steven M Horwitz; Marco Ruella
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 3.952

Review 5.  How we treat NK/T-cell lymphomas.

Authors:  Eric Tse; Wei-Li Zhao; Jie Xiong; Yok-Lam Kwong
Journal:  J Hematol Oncol       Date:  2022-06-03       Impact factor: 23.168

Review 6.  Immunologic Milieu of Mature T-Cell and NK-Cell Lymphomas-Implications for Therapy.

Authors:  Eric Tse; Yok-Lam Kwong
Journal:  Curr Hematol Malig Rep       Date:  2018-02       Impact factor: 3.952

Review 7.  Treatment Advances in EBV Related Lymphoproliferative Diseases.

Authors:  Kebing Lv; Ting Yin; Min Yu; Zhiwei Chen; Yulan Zhou; Fei Li
Journal:  Front Oncol       Date:  2022-04-19       Impact factor: 5.738

Review 8.  Mechanisms of Immune Evasion and Immune Modulation by Lymphoma Cells.

Authors:  Thomas Menter; Alexandar Tzankov
Journal:  Front Oncol       Date:  2018-03-07       Impact factor: 6.244

9.  Synergistic effects of low‑dose chemotherapy and T cells in renal cell carcinoma.

Authors:  Dan-Dan Xu; Men Ding; Pan Tong; Yan-Yun Chong; Wei-Yu Gu; Yang Li; Xin-Jiang Fang; Ning Li
Journal:  Oncol Rep       Date:  2020-07-07       Impact factor: 3.906

Review 10.  Extranodal NK/T cell lymphoma.

Authors:  Seong Hyun Jeong
Journal:  Blood Res       Date:  2020-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.